Top 50 Medical VC (Venture Capital) Funds in Denmark in April 2025

Investor	Medical Denmark investments
BioInnovation Institute	12
Novo Holdings	9
Vaekstfonden	6
Vaekstfonden	4
Export and Investment Fund	4
Sunstone Life Science Ventures	4
Seed Capital	3
Forbion Capital Partners	2
VentureFriends	2
Industrifonden	2
PSV	2
Crowberry Capital	2
CAPNOVA	2
Innovation Fund Denmark	2
People Ventures	2
Wellcome Trust	2
Sound Bioventures	1
CBC Investment Group	1
M Ventures	1
V-Bio Ventures	1
European Investment Bank	1
BlueYard Capital	1
+ND Capital	1
Seventure Partners	1
Teknoinvest	1
Bioqube Ventures	1
New Enterprise Associates	1
VF Venture	1
Den Midtjyske Inværksätterfond	1
Bossanova Investimentos	1
SEB Venture Capital	1
BankInvest Biomedical Venture	1
Dansk Erhvervsinvestering	1
Noble Resources	1
Innovestor	1
VIB	1
Inovo.vc	1
AdBio partners	1
Roche Venture Fund	1
Nucleus Capital	1
Sanofi Ventures	1
p53	1
LS Polaris Innovation Fund	1
EASME	1
Eli Lilly	1
North Ventures	1
Nucleus Capital	1
LF Investment	1
Amino Collective	1
Biofund	1

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Investment focus

Biotechnology, Medical, Health Care
Convertible Note, Pre-Seed, Debt Financing
Denmark, Germany, Switzerland

Portfolio highlights

NorFalk — Our website is currently being redesigned. Thank you for your patience!
ArcanaBio — ArcanaBio is developing realtime biosurveillance solutions that minimize workplace disruptions and support health & wellness
Fuse Vectors — Fuse Vectors is disrupting the manufacturing process in order to provide universal access to gene therapy.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Supira Medical — Next Generation Solution for Temporary Mechanical Circulatory Support Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock. Clinical Need Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of
Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.
Newleos Therapeutics — Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Investment focus

Software, Information Technology, SaaS
Seed, Funding Round, Pre-Seed
Denmark, United States, United Kingdom

Portfolio highlights

Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
Keepit — The Keepit Cloud is the most cost-effective solution on the market with 20+ years of experience. Learn more about our next-level data protection services
kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Investment focus

Software, SaaS, Information Technology
Seed, Funding Round, Pre-Seed
Denmark, United States, Norway

Portfolio highlights

Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
Keepit — The Keepit Cloud is the most cost-effective solution on the market with 20+ years of experience. Learn more about our next-level data protection services
kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.

Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Funding Round
Denmark, United States, United Kingdom

Portfolio highlights

Orbex Space — Founded in 2015, Orbex is Europe’s leading private launch services company, focused entirely on supporting the needs of the small satellite industry.Orbex has developed one of the most advanced, low carbon, high performance micro-launch vehicles in the world. They launch customer satellites into polar and sun-synchronous low Earth orbits from aunique, modern launch location in the heart of the European continent.They offer a flexible core launch service and a wide suite of supporting services that make life easier for customers. Their European location means shorter supply lines, easier communications and reduced operational costs. Their advanced launch vehicle means higher reliability, more flexible mission profiles and a regular, scheduled launch service.
Fuse Vectors — Fuse Vectors is disrupting the manufacturing process in order to provide universal access to gene therapy.
Capra Robotics — Our Mobile Robot Platform is a versatile solution optimized for outdoor use in any terrain. Read more about how the CAPRA can work for you.

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
Denmark, Sweden, Switzerland

Portfolio highlights

Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.

Investment focus

Software, Health Care, SaaS
Seed, Funding Round, Series A
Denmark, United States, United Kingdom

Portfolio highlights

Tembi — Market Intelligence platform with deep market data, insights and predictions for B2B companies that look for a competitive edge.
Landfolk — Landfolk is the new marketplace for the special holiday homes that are hidden around the country. We have hand-picked every single cottage, where there are proud and passionate hosts, who love their holiday homes, but also like to share it with others.
Embankment Group — Embankment Group is a recruitment consultancy specialising in candidate short markets. We pride ourselves on matching the best talent to the right companies.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Numab — Numab Therapeutics AG
Verdiva Bio — Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

Backing ambitious early-stage founders across Europe and MENA

Investment focus

FinTech, E-Commerce, Software
Seed, Series A, Pre-Seed
Greece, United Kingdom, United States

Portfolio highlights

Capalo AI — We maximize the value of your energy storage systems. Now and in the future.
Merx — Merx is a conversational commerce platform that enables brands to interact with shoppers through messaging channels, facilitating meaningful conversations and enhancing customer engagement. The platform offers tools for automating customer interactions, managing inquiries, and providing personalized responses, allowing sales teams to streamlinetheir communication processes. By integrating with various messaging applications, Merx helps businesses reach customers in real-time, improving response times and increasing conversion rates. Additionally, the platform provides analytics and insights to help brands understand customer behavior and preferences, supporting informed decision-making for sales strategies.
Edgee — Edgee is a full-stack edge platform that aims to alter how workloads and data are processed on the internet. A variety of services are offered by the Edgee platform for edge-based applications.

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Investment focus

Software, Biotechnology, Information Technology
Funding Round, Series A, Seed
Sweden, United States, Denmark

Portfolio highlights

Fibbl — Fibbl is the world's first cost-effective end-to-end solution for 3D and AR focused visual marketing. Integrate 3D & AR into e-commerce and marketing in minutes.Fibbl have industrialized the process of producing photorealistic 3D models for consumer products from global brands. Fibbl has the world's largest 3D model database forconsumer products.Learn more - https://www.fibbl.com/
Agteria Biotech — Agteria Biotech is an innovative biotech startup dedicated to mitigating methane emissions in cattle through our groundbreaking compound. By promoting sustainable practices in livestock farming, we aim to engage investors and dairy companies interested in eco-friendly solutions. Partner with us to t
Senseworks — Senseworks is an insight platform that enables colleagues to collaborate effectively with customers by providing a single source of truth for accounting data.

PreSeed Ventures are the preferred travel companion for trailblazing founders when they set out on the journey of transforming startup dreams to successful businesses. Founded in 2000 they have an exceptional track record of spotting, fostering and financing tomorrow’s winners in syndication with top-tier investors locally and globally. As the namesuggests, PreSeed Ventures operates at the earliest stages, where founders need the professional, operational & systematic support of a VC, but the risks are still too high for most VCs in seed stages. Yet to the powerhouse of experts behind PreSeed Ventures, who have experience from hundreds of startup journey in the pre-seed stage, it is an opportunity to support and nurture the growth of promising startups on the rise, minimizing the time and risk to the next investment round.PreSeed Ventures has grown out of the technological research environment at Denmark’s Technical University, DTU. In 2020 they launch their first full blown commercial venture fund, yet continuing to be a subsidiary company to the university.

Investment focus

Software, Information Technology, SaaS
Seed, Pre-Seed, Funding Round
Denmark, United States, United Kingdom

Portfolio highlights

Cellugy — Biomaterial to Replace Plastic
ZTLment — We empower online platforms and marketplaces to seamlessly hold, manage, and distribute funds in real-time, with full automation and compliance.
Dynelectro — Dynelectro is a Danish solid oxide electrolyser equipment manufacturer with proprietary innovation to lower the total cost of hydrogen. Dynamic operation enables load-follow of fluctuating renewable energy, delivering over 85% electrical efficiency prior to integrating with industrial heat sources. With fully reversable operation, electricity generation adds substantial value and flexibility with grid ancillary services. Small-scale units begin at 40 kW with 12-month lead time. Large-scale systems start at 1 MW with project-based lead time.

Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.

Investment focus

Software, Gaming, Health Care
Seed, Series A, Pre-Seed
Iceland, Denmark, Finland

Portfolio highlights

Tiimo — Tiimo helps you manage your daily life and improve your wellbeing. Visualize your day. Improve your routines. Stress less.
Quanscient — We are building next generation simulation software-as-a-service utilizing Quantum computing algorithms. Our specialty domain of simulations is Computational Electromagnetics.
Porcelain Fortress — Porcelain Fortress was founded by a small band of romantics in the summer of 2016 in Reykjavik, Iceland.

They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg.

Investment focus

Software, Information Technology, Internet
Funding Round, Seed, Pre-Seed
Denmark, United States, India

Portfolio highlights

Ulobby — Ulobby is an automated tool for stakeholder management and political monitoring
Mechanic Miner — Mechanic Miner is a 2D construction/survival game with mechanical steam-powered machines. You are stranded on a strange and forbidding planet, where survival is made difficult by hostile animals and plant life. From your home world you did bring a multitool, which is able to craft any kind of machine part - provided the requisite rawmaterials can be found. Relying solely on the technology you brought, you set out to explore a whole world. You can progress through the game by acquiring new types of steam-powered technology elements, that are necessary to delve deeper into the diverse biomes of the planet, and perhaps, ultimately, discover the means to escape. You can construct any kind of machine of your own design - and any kind of machine can be simulated by the game's physics engine - and of course, designs can be shared with your friends.
ResoTher Pharma — ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin 1A as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role.

Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.

Investment focus

Software, Biotechnology, SaaS
Grant, Pre-Seed, Seed
Denmark, United States

Portfolio highlights

SureShot — SureShot empowers you and your audience to become video co-creators. With our cutting-edge AI, capture, edit, and share electrifying videos that amplify the essence of every event.
FEESH — FEESH is a groundbreaking biotech company developing sustainable protein alternatives targeted at the aquaculture industry.
Tailwind Biotech — AI-powered synthetic DNA design services for improved strain development. We use Artificial Intelligence to help biotech companies achieve more effective and more efficient bioproduction processes. Our technology designs best-in-class synthetic DNA Promoters and Terminators, and performs gene codon optimizations that help to maximise biomanufacturing yields while reducing development costs.

People Ventures are your dreamcast team of co-founders, investors, executives, engineers, academics and industry experts. Together with talented entrepreneurs — We shape fantastic businesses through operational and commercial execution.

Investment focus

Health Care, Internet of Things, Software
Seed, Pre-Seed, Series A
Denmark, Sweden, United States

Portfolio highlights

Tiimo — Tiimo helps you manage your daily life and improve your wellbeing. Visualize your day. Improve your routines. Stress less.
proemial — Smart summaries. Instant answers. For everything your team shares in Slack.
Version Lens — Meet your new Product Management Co-Pilot. Reduce overhead for your product team so you can focus on what truly matters, building outstanding products.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Series C, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

RenBio — RenBio develops antibody-based therapeutic solutions for the treatment of cancer and inflammatory diseases. RenBio's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint and antibody factory.
Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Sound Bioventures is a venture capital fund investing in clinical stage companies.

Investment focus

Medical, Biotechnology, Therapeutics
Series A, Seed, Series B
France, Denmark, United States

Portfolio highlights

VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.

CBC Investment Group started in 2009 in the midst of the financial crisis. The banks were on their knees, start-ups of small and medium-sized companies - all of a sudden they saw their credit and credit promises turned into demands for quick repayment and empty words. Serious talented entrepreneurs' ideas and companies risked going completelyunnecessary. In response to this crisis, they started the CBC Investment Group.

Investment focus

Biotechnology, Software, SaaS
Funding Round, Seed, Series B
Sweden, Denmark, Germany

Portfolio highlights

GLX Analytix — GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark.
Swiftly — World's first AI that applies for jobs. Say goodbye to creating CV's, searching and applying for jobs. Let Swiftly do it for you! Welcome to the new age.
Hugel Control — HUGEL, Inc. strives to be a global company that continuously creates innovative products, promotes universal health, and improves the quality of life through state-of-the-art technology and creativity.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
Formo — We're Formo, the future of dairy. Using micro fermentation, we create animal-free cheeses that humans love.
NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Seed
Belgium, France, United Kingdom

Portfolio highlights

ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
Confo Therapeutics — Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.
Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union.The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds;equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds.The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises.EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors.European Investment Bank was founded in 1958 and is based in Luxembourg.

Investment focus

Biotechnology, Health Care, Energy
Debt Financing, Post-IPO Debt, Funding Round
France, Germany, The Netherlands

Portfolio highlights

BURN — The future of clean cooking
GEWOBA — GEWOBA is a real estate company that manages and provides a diverse portfolio of rental real estate apartments and properties.
Acea — Acea operates in six business segments. The water segment collects, purchases, transports and distributes drinking water, and manages the sewerage system and the purification of wastewaters. The company serves 9 million residents served in Lazio, Tuscany, Umbria, Molise and Campania; The energy segment manages the transmission and distributesroughly 9 TWh of electricity, public lighting; commercial and trading segment activities include energy management, sale of electricity and gas, energy efficiency for domestic customers. The company is targeting growth in electricity generation from renewable (photovoltaic) sources and in electric mobility, with a view to effectively contributing more and more to the energy transition and decarbonisation. The environment segment provides laboratory, research and related consultancy services on the environment and control functions within the water cycle; engineering services and overseas operations providing water services in Latin America.

BlueYard backs founders building the interconnected elements that can become the fabric of our future.

Investment focus

Software, Biotechnology, Internet
Seed, Series A, Funding Round
United States, Germany, United Kingdom

Portfolio highlights

bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
Cryptio — We offer enterprise-grade accounting, reporting, and audit software for your digital assets.
Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.

+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, Switzerland, Denmark

Portfolio highlights

Vandria — At the vanguard of Mitochondrial research
Constructive Bio — Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things.
PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Investment focus

Biotechnology, Health Care, Software
Series A, Funding Round, Series B
France, United States, Germany

Portfolio highlights

Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
Allozymes — Allozymes applies its proprietary platform technology to rapidly develop novel enzymes, revolutionizing the way that industries manufacture complex natural
Vedanta Biosciences — Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VCÂ´s in Scandinaviaaccording to track record of value created for their investors.

Investment focus

Biotechnology, Health Care, Medical
Series B, Funding Round, Series A
Sweden, Norway, United States

Portfolio highlights

GLO — glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who haspublished more than 500 papers related to this technology.glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications.glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications.glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized.glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications.
SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The companyâ€™s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the companyâ€™s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
Sol Voltaics — Founded in 2007, Sol Voltaics AB is a venture-backed, development-stage nanotechnology company focused on development and commercialization of highly efficient, third-generation photovoltaic concentrator solar cells based on its proprietary heterostructured nanowire epitaxial growth and process technologies.

A life science venture capital fund - investing globally in exciting science to accelerate breakthrough therapies in patients.

Investment focus

Biotechnology, Therapeutics, Life Science
Seed, Series A, Series B
United States, France, Denmark

Portfolio highlights

CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
Commit Biologics — Add a description for facebook
SynOx Therapeutics — SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.

Foundational partners to ambitious founders at every stage of company-building.

Investment focus

Software, Health Care, Biotechnology
Series B, Series A, Series C
United States, India, Canada

Portfolio highlights

Ceramic.ai — Ceramic.ai builds enterprise-grade infrastructure to optimize how companies train and deploy their AI models
Vori Health — Meet Vori Health, the new virtual and in-person musculoskeletal healthcare company that will help you get that spring back into your step.
Ceramic — Next generation AI training systems for better models with less compute, less time, and lower costs.

Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.

Investment focus

Software, Biotechnology, SaaS
Seed, Funding Round, Series A
Denmark, United Kingdom, Iceland

Portfolio highlights

Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
Onomondo — Onomondo is a global IoT network. Our IoT SIM and cloud platform future proof your devices with full data transparency, freedom to leave, and no third parties.

The Midtjyske Ivaerksätterfond invests in entrepreneurial enterprises that are knowledge-intensive and innovative in order to produce growth, jobs, and value.

Investment focus

Medical, Health Care, Biotechnology
Seed
Denmark

Portfolio highlights

MedicQuant — MedicQuant is a medical equipment manufacturing company developing diagnostic kits for blood anticoagulant properties. The company's novel technology, chip, and instrument, Direct Oral Anticoagulants (DOACs), detect blood levels of the anticoagulants, directly from whole blood.

Somos Bossa Invest

Investment focus

Software, Information Technology, Financial Services
Seed, Pre-Seed, Funding Round
Brazil, United States, Mexico

Portfolio highlights

SenseUp — SenseUp provides IoT, big data, machine learning, and computer vision for the real-time needs of the financial market. It improves the way organizations interact with data by using microintegrations to orchestrate different data sources, consumers, and data flows in support of processes and decision-making.
Emitter — Emissor de CTe e NFSe em massa mais simples e rápido, acesse e conheça todas as soluções para sua empresa, emitir CTe de forma simples.
Hiperbanco — O Hiperbanco é uma Fintech que oferece diversos serviços financeiros, com destaque para o produto “Banco Digital Whitelabel”. Seu público-alvo abrange empresas de diversos setores, que buscam soluções financeiras flexíveis e personalizadas com sua marca, como Conta, PIX, TED, Boleto, Recargas, Cartão, Emprestimos, dentre outros. Os principaisdiferenciais do Hiperbanco incluem sua abordagem centralizada no cliente, desenhando juntos um produto financeiro único e atuando com tecnologias de ponta.

SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.

Investment focus

Software, Information Technology, Financial Services
Funding Round, Series A, Series B
Sweden, Denmark, United Kingdom

Portfolio highlights

Airsonett — Research-based medical technology company which leads the way in the development of non-pharmaceutical treatment for allergic asthma.
EnginZyme — EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating.The company is driven by a mission to make biocatalysis the first choice for chemical process designersworldwide.
Qvantum — Qvantum is driven by a passion for a sustainable future and we are changing the way the cities of Europe are heated.

BankInvest Biomedical Venture makes investments in research-based biotechnology companies in Europe.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series C
Denmark, United Kingdom, France

Portfolio highlights

F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
Nereus Pharmaceuticals — Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent forthe treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
Resistentia Pharmaceuticals — Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiplesclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.

Dansk Erhvervsinvestering is a company that assists individuals with investing.

Investment focus

Medical, Health Care, Biotechnology
Funding Round
Denmark

Portfolio highlights

Genmab — Genmab is an international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's discovery, development, and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Its primary goal is to improve the lives ofpatients who are in urgent need of new treatment options.
PremiTech — PremiTech A/S develops systems management software. It offers Performance Guard, a solution that enables IT departments to get real-time measurement of end-user application and infrastructure IT performance in software as a service model. The company also provides Performance Guard CIO Dashboard Module, which provides a view into the ITinfrastructures performance based on grouping by location and application; and Performance Guard Health Check Module that delivers reports on infrastructure components, including applications, mid-tier servers, network and PC Infrastructure for automated, out-of-the-box fast performance documentation, and issue resolution. In addition, it offers monitoring and documentation, and performance monitoring solutions. The company has strategic partnerships with HP, Computer Associates, BMC, VMWare, IBM, and Microsoft. PremiTech A/S was founded in 1999 and is headquartered in Hedehusene, Denmark. As of 2008, PremiTech A/S operates as a subsidiary of CapaSystems A/S.

Noble Group is a global supply chain manager of energy, power & gas products, metals and carbon steel materials, with interests in key facilities that add value at various stages of its supply chains. Noble Group manages a diversified portfolio of essential natural resources, with integrated sourcing, marketing, processing, financing andtransportation operations. Noble Group's Energy segment encompasses a portfolio of oil liquids and coal products and continues to be a significant driver for the Group’s growth. Gas & Power segment includes their retail energy business Noble Americas Energy Solutions and Gas & Power wholesale operations. In Metals & Mining, Noble Group is one of the world’s leading suppliers with interests in iron ore, aluminium, special ores and alloys across key global locations. The Corporate segment incorporates the Logistics business as well as investments in their major associates. Noble Group (SGX: N21) manages a portfolio of global supply chains covering a range of industrial and energy products. Operating from over 60 locations, Noble facilitates the marketing, processing, financing and transportation of essential raw materials. Sourcing bulk commodities from low cost regions such as South America, South Africa, Australia and Indonesia, the Group supplies high growth demand markets, particularly in Asia and the Middle East. Noble Group is ranked number 77 in the 2015 Fortune Global 500. Noble moves essential resources from producers to consumer across the world. Noble Group's success relies on a rigorously managed balance sheet, effective partnerships and a deep understanding of customer needs. Noble’s core strategy is to be the best company in the world at moving the physical commodity from the producer to the consumer and managing the market, credit and operational risk associated with that. Noble Group's solid financial position comes from a rigorously managed balance sheet with exceptional liquidity and a carefully guided exposure to risk - underpinned by deep relationships with global capital providers. At Noble, they have forged some of the most productive and enterprising partnerships in the industry and they have always believed that as their partners grow, so do they. Noble Group put energy and focus into staying relevant and being valuable to their customers, keeping their interests firmly integrated into their DNA.

Investment focus

Medical, Health Care, Genetics
Funding Round
Denmark, United Kingdom

Portfolio highlights

Exiqon — Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and thedevelopment of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.
Digital-Healthcare — Digital Healthcare is a health care company. The company has been acquired by EMIS Group.

Innovestor is an active Finnish investment manager, focusing on venture capital, real estate, and energy storage. We also offer corporate venturing services.

Investment focus

Software, Health Care, Manufacturing
Seed, Funding Round, Series A
Finland, Denmark, Sweden

Portfolio highlights

Aplagon — Aplagon is committed to bringing unique, effective antithrombotic medicines with important safety advantages to patients with unmet needs.
Bahn Express — Fast and Effortless Car Transport
Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se

Strategic research in on life sciences and biotechnology

Investment focus

Biotechnology, Pharmaceutical, Health Care
Series A, Series B, Funding Round
Belgium, Brazil, Denmark

Portfolio highlights

Protealis — Sustainable plant proteins for Europe
Confo Therapeutics — Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.
Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

VC for the most ambitious founders in CEE

Investment focus

Software, B2B, Apps
Seed, Pre-Seed, Series A
Poland, United States, Italy

Portfolio highlights

SplxAI — The SplxAI platform is the first complete pentesting solution for Conversational AI apps. Secure your AI systems proactively with automated vulnerability assessments and mitigation.
Pythagora — Dev tool that uses AI to generate integration tests by analysing server activity without the developer having to write a single line of code
Quantia — A powerful and easy to use analytics platform for tracking, analyzing and understanding the performance of your brand in the ecommerce world.

AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Series A, Funding Round
France, Spain, Belgium

Portfolio highlights

Cephagenix — Cephagenix focuses on identifying and developing new, effective migraine therapies.
Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.
Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Spain

Portfolio highlights

DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team Latest News See more Our Work OUR APPROACH ABOUT DIABETES
Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

Supporting purpose-driven founders solving systemic challenges to planetary health.

Investment focus

Biotechnology, Information Technology, Food and Beverage
Pre-Seed, Seed, Series A
Germany, United Kingdom, United States

Portfolio highlights

Planet A Foods — The chocolate revolution is here. 100% cocoa-free and unbelievably delicious. We call it QOA. You need to try it!
Ucaneo — We Leveraging the magic of the human body to remove CO2 from the air.
Endolith — Endolith is a biotech company transforming sustainable mining by leveraging microbes, synthetic biology, and cloud computing to extract more critical minerals like copper from low-grade ores. Working with the many of the leading mining companies, Endolith is advancing its innovative technology to commercial scale. Recognized as a finalist in theBHP Unearthed BioMetals cohort and a member of the Alaska Critical Minerals Collaborative, Endolith is driving the future of mining with sustainable, efficient, and responsible solutions for the clean energy transition.

Sanofi Ventures invests in top tier biotherapeutic and digital health entrepreneurs who focus on helping patients and transforming the healthcare system.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, France

Portfolio highlights

AdvanCell — AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.

p53 identifies and invests in innovative healthcare companies, particularly in the fields of biotechnology and medical devices.

Investment focus

Biotechnology, Medical, Life Science
Series A
Norway, Denmark

Portfolio highlights

Calluna Pharma — Join Calluna Pharma to transform therapeutics for inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, we can revolutionize patient care.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.

The LS Polaris Innovation Fund aims to accelerate the commercial and therapeutic potential of early stage academic research.

Investment focus

Biotechnology, Medical, Biopharma
Series A, Series B, Funding Round
United States, Denmark

Portfolio highlights

Glympse Bio — Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platformtechnology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.
Satellite Bio — Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.

Executive Agency for SMEs

Investment focus

Biotechnology, Health Care, Software
Grant, Seed, Funding Round
Spain, United Kingdom, Switzerland

Portfolio highlights

AGADE — Esoscheletri Agade | Il primo esoscheletro intelligente per lavoratori progettato per ridurre il rischio di disturbi muscolari delle spalle nella movimentazione manuale dei carichi.
BroadBit Batteries — BroadBit is a technology company developing revolutionary new batteries using novel sodium-based chemistries to power the future green economy.
Aenitis Technologies — We develop innovative devices for cells therapy processing using Acoustic Radiation Forces.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conductsresearch to find products to treat diseases in animals and to increase the efficiency of animal food production.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Funding Round
United States, United Kingdom, Canada

Portfolio highlights

Maxion Therapeutics — Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets.
Ampersand Biomedicines — Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability.
Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

North Ventures is a venture capital firm that invests in technology-driven startups from seed to Series A.

Investment focus

Financial Services
Series A
Denmark

Portfolio highlights

Monthio — Embrace the future of lending with Open Banking for credit decisioning. Streamline loan applications, increase accessibility, and deliver exceptional customer service.
Cerebriu — Cerebriu is a health tech company developing machine learning in medical imaging that improves workflow efficiency and quality in radiology.Its software solution Cerebriu Apollo achieves the company's aim by automating image acquisition protocols and triage during MRI brain acquisition providing decision support at key stages of thediagnostic process. The company covers findings of the brain, starting with brain MRI, including stroke, bleeds, and tumors, following MS, dementia, and TBI in brain CT.

Supporting purpose-driven founders solving systemic challenges to planetary health.

Investment focus

Biotechnology, Information Technology, Food and Beverage
Pre-Seed, Seed, Series A
Germany, United Kingdom, United States

Portfolio highlights

Planet A Foods — The chocolate revolution is here. 100% cocoa-free and unbelievably delicious. We call it QOA. You need to try it!
Ucaneo — We Leveraging the magic of the human body to remove CO2 from the air.
Izote Biosciences — Biomanufacturing Scale-Up Solution

LF Investment is the investment arm of The Lauritzen Foundation, which is the parent company of the shipping companies J. Lauritzen (wholly-owned) and DFDS (42,8% holding). LF Investment has holdings in companies in the oil analysis, measuring equipment, software, biotechnology, and real estate sectors.

Investment focus

Medical, Wellness, Health Care
Funding Round
Denmark

Portfolio highlights

Minervax — We are MinervaX. A clinical stage biotech company focused on making a global impact by developing state-of-the-art vaccines.

Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.

Investment focus

Health Care, Biotechnology, Medical
Seed, Pre-Seed, Series A
United States, Germany, United Kingdom

Portfolio highlights

Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
ExpressionEdits — Redefining the status quo of protein expression
Tandem Health — Focus on providing care, while Tandem helps you easily write medical notes directly after the patient consultation.

BIOFUND SpA, established by Fondazione Monte dei Paschi, Bank Monte dei Paschi , Finanziaria Senese di Sviluppo e Fidi Toscana, provides the initial seed capital for companies located in the incubator of Toscana Life Sciences in Siena.

Investment focus

Genetics, Medical, Health Care
Funding Round, Seed
Canada, Denmark, Russian Federation

Portfolio highlights

Exiqon — Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and thedevelopment of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.
RTM Diagnostika — Diagnostic microwave radio RTM-01-RESThe temperature and rate of growth of malignant tumorsCancer is the terrible disease of breast. That is why the full range of diagnostic measures in mammalogy aimed primarily at identifying it. It is known that the malignant tumor has a higher temperature compared with surrounding tissues. These data werefirst obtained Guture M. French scientist, who, after more than 550 invasive measurements demonstrated that malignancy is determined by its temperature is doubling time. Therefore, the most dangerous, rapidly growing tumors have a very high temperature. It is also known that thermal changes, usually preceded by structural changes. In particular, the thermal changes of the mammary glands come not a moment when the cancer reaches the required size, but much earlier. Studies have shown that even at the stage preceding the malignant growth, namely, when the cells have the expressed proliferation, accompanied by atypical changes, increases the density of microcapillary network, and as a consequence there is a local increase in temperature. Indisputable is the fact that patients with these changes have a high risk of malignancy. Many authors classify this condition as precancerous.The internal temperature - measure of angiogenesisIn 2003, Japanese scientists have shown that the temperature in the cancerous region determined by the density microcapillary network (microvessel density (MVD) [8]. This is the main parameter that characterizes angiogenesis. The density of the microcapillary network when proliferation atypia several times greater than the rate for normal tissues and characterizes the risk of malignancy. in addition, the microcapillary network density refers to the probability of transformation from noninvasive to invasive cancer, the probability of metastasis and tumor growth rate. Therefore, the internal temperature, as a measure of angiogenesis, provides important information about the development of cancer.
Genizon BioSciences — Since 2005, we have helped thousands of people get the perfect domain name.